Giant cell tumor of bone under Denosumab treatment

Joint Bone Spine. 2018 Jul;85(4):491. doi: 10.1016/j.jbspin.2017.09.012. Epub 2017 Sep 29.

Authors

Daniel Wendling¹, Xavier Guillot², Maxime Sondag², Loic Chaigneau³, Sébastien Aubry⁴, Clément Prati²

Affiliations

¹ Department of Rheumatology, CHRU de Besançon, boulevard Fleming, 25030 Besançon, France. Electronic address: [email protected].
² Department of Rheumatology, CHRU de Besançon, boulevard Fleming, 25030 Besançon, France.
³ Department of Clinical Oncology, CHRU de Besançon, 25030 Besançon, France.
⁴ Department of Musculoskeletal Imaging, CHRU de Besançon, 25030 Besançon, France.

PMID: 28970075
DOI: 10.1016/j.jbspin.2017.09.012

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Bone Density Conservation Agents / therapeutic use*
Bone Neoplasms / diagnostic imaging
Bone Neoplasms / drug therapy*
Denosumab / therapeutic use*
Female
Follow-Up Studies
France
Giant Cell Tumor of Bone / diagnostic imaging
Giant Cell Tumor of Bone / drug therapy*
Humans
Ilium / diagnostic imaging
Ilium / drug effects
Injections, Subcutaneous
Risk Assessment
Tomography, X-Ray Computed / methods
Treatment Outcome

Substances

Bone Density Conservation Agents
Denosumab